Greg Fanning

Gregory Fanning is currently the Chief Business Officer at AstriVax and an Advisor at ExeVir, RNAssist, CommBio Therapeutics, SCG Cell Therapy, and Si3. In the past, Gregory has held various leadership roles at The Janssen Pharmaceutical Companies of Johnson & Johnson and worked as a Senior Scientist at Johnson & Johnson. Gregory holds a DPhil in Genetics and Immunology from the University of Oxford.